Combinational therapies for HIV: A focus on EVG/COBI/FTC/TDF

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 13, 2012, Pages 1969-1983

  Schrijvers, Rik ^a,b   Debyser, Zeger ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Cobicistat; Elvitegravir; HIV; Integrase inhibitors; Quad ; Single tablet regimens

Indexed keywords

572 TRII PILL; ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; CALCIUM; COBICISTAT; DIDANOSINE; DOLUTEGRAVIR; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ELVITEGRAVIR; EMTRICITABINE; EMTRICITABINE PLUS RILPIVIRINE PLUS TENOFOVIR DISOPROXIL; ETHINYLESTRADIOL; ETRAVIRINE; GS 913; HISTAMINE H2 RECEPTOR ANTAGONIST; INTEGRASE; IRON; KETOCONAZOLE; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; MARAVIROC; PROTON PUMP INHIBITOR; QUAD; RIFABUTIN; RILPIVIRINE; ROSUVASTATIN; STAVUDINE; TENOFOVIR DISOPROXIL; TIPRANAVIR; UNCLASSIFIED DRUG; ZINC;

ANTIVIRAL RESISTANCE; ARTICLE; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; LUNG TUBERCULOSIS; MEDLINE; NAUSEA AND VOMITING; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SINGLE DRUG DOSE; TERATOGENICITY; VIRUS GENE; VIRUS LOAD; VIRUS MUTATION;

ADENINE; ANTI-HIV AGENTS; CARBAMATES; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DEOXYCYTIDINE; DRUG COMBINATIONS; DRUG RESISTANCE, MULTIPLE, VIRAL; HIV INFECTIONS; HUMANS; ORGANOPHOSPHONATES; QUINOLONES; THIAZOLES;

EID: 84865347019     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.712514     Document Type: Article

References (96)

1. Mitsuya H, Weinhold KJ, Furman PA, et al. 3′-Azido-3′- deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy- associated virus in vitro. Proc Natl Acad Sci USA 1985;82(20):7096-100 (Pubitemid 16209699)
2. De Clercq E. The history of antiretrovirals: key discoveries over the past 25 years. Rev Med Virol 2009;19(5):287-99
3. Marchand C. The elvitegravir Quad pill: the first once-daily dual-target anti-HIV tablet. Expert Opin Investig Drugs 2012; Epub ahead of print
4. Staszewski S, Keiser P, Montaner J, et al. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: a randomized equivalence trial. JAMA 2001;285(9):1155-63 (Pubitemid 32198480)
5. Matheron S, Descamps D, Boue F, et al. Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nelfinavir as first-line therapy in HIV-1-infected adults: a randomized trial. Antivir Ther 2003;8(2):163-71 (Pubitemid 36565897)
6. Gulick RM, Ribaudo HJ, Shikuma CM, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004;350(18):1850-61 (Pubitemid 38917251)
7. Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 1-240. Available from: http://www.aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf [Accessed 10 May 2012]
8. Shey M, Kongnyuy EJ, Shang J, Wiysonge CS. A combination drug of abacavir-lamivudine-zidovudine (Trizivir) for treating HIV infection and AIDS. Cochrane Database Syst Rev 2009(3):CD005481
9. Smith KY, Patel P, Fine D, et al. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS 2009;23(12):1547-56
10. Pozniak AL, Gallant JE, DeJesus E, et al. Superior outcome for tenofovir DF (RDF), emtricitabine (FTC) and efavirenz (EFV) compared to fixed dose zidovudine/lamivudine (CBV) and EFV in antiretroviral naïve patients [abstract no. WeOa0202]. The 3rd IAS Conference on HIV Pathogenesis and Treatment; 24-27 July 2005; Rio de Janeiro, Brazil
11. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006;354(3):251-60 (Pubitemid 43113030)
12. Rodriguez-Rosado R, Jimenez-Nacher I, Soriano V, et al. Virological failure and adherence to antiretroviral therapy in HIV-infected patients. AIDS 1998;12(9):1112-13 (Pubitemid 28276985)
13. Yuen GJ, Lou Y, Thompson NF, et al. Abacavir/lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with each component administered concurrently and the effect of food on absorption. J Clin Pharmacol 2001;41(3):277-88 (Pubitemid 32184980)
14. Mathias AA, Hinkle J, Menning M, et al. Bioequivalence of efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen. J Acquir Immune Defic Syndr 2007;46(2):167-73 (Pubitemid 47482611)
15. Airoldi M, Zaccarelli M, Bisi L, et al. One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects. Patient Prefer Adherence 2010;4:115-25
16. Maitland D, Jackson A, Osorio J, et al. Switching from twice-daily abacavir and lamivudine to the once-daily fixed-dose combination tablet of abacavir and lamivudine improves patient adherence and satisfaction with therapy. HIV Med 2008;9(8):667-72
17. Opravil M, Hirschel B, Lazzarin A, et al. A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. J Infect Dis 2002;185(9):1251-60 (Pubitemid 34439132)
18. Dejesus E, Young B, Morales-Ramirez JO, et al. Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients. J Acquir Immune Defic Syndr 2009;51(2):163-74
19. Hodder SL, Mounzer K, Dejesus E, et al. Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF. AIDS Patient Care STDS 2010; 24(2):87-96
20. Bangsberg DR, Ragland K, Monk A, Deeks SG. A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people. AIDS 2010;24(18):2835-40
21. Sax PE, Meyers JL, Mugavero M, Davis KL. Adherence to antiretroviral treatment and correlation with risk of hospitalization among commercially insured HIV patients in the United States. PLoS ONE 2012;7(2):e31591
22. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010;304(3):321-33
23. Sax PE, Tierney C, Collier AC, et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med 2009;361(23):2230-40
24. Cohen CJ, Andrade-Villanueva J, Clotet B, et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet 2011;378(9787):229-37
25. Molina JM, Cahn P, Grinsztejn B, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet 2011;378(9787):238-46
26. Schrijvers R, Desimmie BA, Debyser Z. Rilpivirine: a step forward in tailored HIV treatment. Lancet 2011;378(9787):201-3
27. Wheeler WH, Ziebell RA, Zabina H, et al. Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.-2006. AIDS 2010;24(8):1203-12
28. Maggiolo F. Efavirenz: a decade of clinical experience in the treatment of HIV. J Antimicrob Chemother 2009;64(5):910-28
29. Cohen C, Molina J, Cahn P, et al. Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive, HIV-1-infected patients: pooled results from the phase 3 double-blind, randomized ECHO and THRIVE trials. J Acquir Immune Defic Syndr 2012;60(1):33-42
30. US Food and Drug Administration. Approval of Edurant (rilpivirine) a new NNRTI for the treatment of HIV in treatment naive patients. 2011.Available from: http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/ HIVandAIDSActivities/ucm256151.htm [Accessed 10 May 2012]
31. Mathias AA, German P, Murray BP, et al. Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity. Clin Pharmacol Ther 2010;87(3):322-9
32. Eron JJ Jr, Rockstroh JK, Reynes J, et al. Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. Lancet Infect Dis 2011;11(12):907-15
33. DeJesus E, Berger D, Markowitz M, et al. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. J Acquir Immune Defic Syndr 2006;43(1):1-5 (Pubitemid 44306480)
34. Zolopa AR, Berger DS, Lampiris H, et al. Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial. J Infect Dis 2010;201(6):814-22
35. Molina JM, Lamarca A, Andrade-Villanueva J, et al. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study. Lancet Infect Dis 2012; 12(1):27-35
36. Desimmie BA, Schrijvers R, Debyser Z. Elvitegravir: a once daily alternative to raltegravir. Lancet Infect Dis 2012; 12(1):3-5
37. German P, Mathias A, Wei L, et al. Cytochrome P450 2D6, 2B6 abd O-glycoprotein using phenotypic probes [abstract O-01]. 12th International Workshop on Clinical Pharmacology of HIV Therapy; 13-15 April 2011; Miami, USA
38. Ramanathan S, Wang H, Stondell T, et al. Pharmacokinetics and drug interaction profile of cobicistat boosted-elvitegravir with atazanavir, rosuvastatin or rifabutin [abstract O-03]. 13th International Workshop on Clinical Pharmacology of HIV Therapy; 16-18 April 2012; Barcelona, Spain
39. Ramanathan S, Mathias AA, German P, Kearney BP. Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir. Clin Pharmacokinet 2011;50(4):229-44
40. Cohen C, Elion R, Ruane P, et al. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. AIDS 2011;25(6):F7-12
41. Elion R, Gathe J, Rashbaum B, et al. Single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF; "QUAD") maintains a high rate of virologic suppression, and cobicistat (COBI) is an effective pharmacoenhancer through 48 weeks [abstract H-938B]. 50th Interscience conference on Antimicrobial Agents and Chemotherapy (ICAAC); 12-15 September 2010; Boston, USA
42. Sax P, DeJesus E, Mills A, et al. Elvitegravir/cobicistat/emtricitabine/ tenofovir (Quad) has non-inferior efficacy and favorable safety compared to efavirenz/emtricitabine/tenofovir in treatment-naïve HIV-1+ subjects [abstract 101]. 19th Conference on Retroviruses and Opportunistic Infections; 5-8 March 2012; Seattle, USA
43. Food and Drug Administration/CDER Web site. Guidance for Industry: Antiretroviral Drugs Using Plasma HIV RNA Measurements-Clinical Considerations for Accelerated and Traditional Approval. 2002. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatory Information/Guidances/UCM070968.pdf [Accessed 10 May 2012]
44. DeJesus E, Rockstroh J, Henry K, et al. Week 48 results of an ongoing global phase 3 study comparing elvitegravir/cobicistat/emtricitabine/tenofovir (Quad) with atazanavir/ritonavir plus emtricitabine/tenofovir in treatment-naive HIV-1+ subjects showing efficacy, safety, and pharmacokinetics [abstract 627]. 19th Conference on Retroviruses and Opportunistic Infections; 5-8 March 2012; Seattle, USA
45. Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009;374(9692):796-806
46. Ramanathan S, Wei X, Szwarcberg J, et al. Exposure/Response Analysis of Once-daily Elvitegravir Administered as Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Single-tablet Regimen in HIV-1+ Patients [abstract 622]. 19th Conference on Retroviruses and Opportunistic Infections; 5-8 March 2012; Seattle, USA
47. Lepist E, Murray B, Tong L, et al. Effect of Cobicistat and Ritonavir on Proximal Renal Tubular Cell Uptake and Efflux Transporters [abstract A1-1724]. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; 17-20 September 2011; Chicago, USA
48. Elion R, Cohen C, Gathe J, et al. Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir DF in the initial treatment of HIV infection. AIDS 2011;25(15):1881-6
49. German P, Lui C, Warren D, et al. Effect of cobicistat on glomerular filtration rate (GFR) in subjects with normal and impaired renal function [abstract H2-804]. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; 17-20 September 2011; Chicago, USA
50. Cooper RD, Wiebe N, Smith N, et al. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis 2010;51(5):496-505
51. DeJesus E, Rockstroh JD, Henry K, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet 2012;379(9835):2429-38
52. Sax PE, DeJesus E, Mills A, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet 2012;379(9835):2439-48
53. Schrijvers R, Debyser Z. Quad's in it for antiretroviral therapy? Lancet 2012;379(9835):2403-5
54. Antiviral Drugs Advisory Committee Meeting Briefing Document (Gilead Sciences). Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (EVG/COBI/FTC/TDF, Quad STR) for treatment of HIV-1 infection in adults. 2012. Available from: http://www.fda. gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ AntiviralDrugsAdvisoryCommittee/UCM303397.pdf [Accessed 11 May 2012]
55. Molina JM, Lamarca A, Andrade-Villanueva J, et al. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study. Lancet Infect Dis 2011;12(1):27-35
56. McColl D, Fransen S, Gupta S, et al. Resistance and cross-resistance to first generation integrase inhibitors: insights from a Phase II study of elvitegravir (GS-9137). Antivir Ther 2007; 12(Suppl 1):S11
57. Waters J, Margot N, Hluhanich RM, et al. Evolution of resistance to the HIV integrase inhibitor (INI) elvitegravir can involve genotypic switching among primary INI resistance patterns [abstract 16]. Antivir Ther 2009;14(Suppl 1):A137
58. Mukherjee R, Jensen ST, Male F, et al. Switching between raltegravir resistance pathways analyzed by deep sequencing. AIDS 2011;25(16):1951-9
59. Quercia R, Dam E, Perez-Bercoff D, Clavel F. Selective-advantage profile of human immunodeficiency virus type 1 integrase mutants explains in vivo evolution of raltegravir resistance genotypes. J Virol 2009;83(19):10245-9
60. Shimura K, Kodama E, Sakagami Y, et al. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J Virol 2008;82(2): 764-74
61. Margot NA, Hluhanich RM, Jones GS, et al. In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4. Antiviral Res 2011;93(2):288-96
62. Goethals O, Clayton R, Van Ginderen M, et al. Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors. J Virol 2008;82(21):10366-74 (Pubitemid 352691161)
63. Kodama E, Shimura K, Sakagami I, et al. In vitro antiviral activity and resistance profile of a novel HIV integrase inhibitor JTK-303/GS-9137 [abstract H-254]. 46th Interscience conference on antimicrobial agents and chemotherapy (ICAAC); 27-30 September 2006; San Francisco, USA
64. Jones GS, Yu F, Zeynalzadegan A, et al. Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase. Antimicrob Agents Chemother 2009;53(3):1194-203
65. Cooper DA, Steigbigel RT, Gatell JM, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008;359(4):355-65
66. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med 2009;17(5):138-45
67. Blanco JL, Varghese V, Rhee SY, et al. HIV-1 integrase inhibitor resistance and its clinical implications. J Infect Dis 2011;203(9):1204-14
68. Metifiot M, Vandegraaff N, Maddali K, et al. Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143. AIDS 2011;25(9):1175-8
69. Reigadas S, Anies G, Masquelier B, et al. The HIV-1 integrase mutations Y143C/R are an alternative pathway for resistance to Raltegravir and impact the enzyme functions. PLoS ONE 2010;5(4):e10311
70. Garrido C, Villacian J, Zahonero N, et al. Broad phenotypic cross-resistance to elvitegravir in HIV-infected patients failing on raltegravir-containing regimens. Antimicrob Agents Chemother 2012;56(6):2873-8
71. Garrido C, Villacian J, Zahonero N, et al. Broad phenotypic cross-resistance to elvitegravir in HIV-infected patients failing on raltegravir-containing regimens. Antimicrob Agents Chemother 2012. [Epub ahead of print]
72. Soriano V, Cox J, Eron J. Dolutegravir (DTG, S/GSK1349572) treatment of subjects with raltegravir (RAL) resistance: viral suppression at week 24 in the VIKING Study [Number PS1/2]. 13th EACS; 12-15 October 2011; Belgrade, Serbia
73. Katlama C, Murphy R. Dolutegravir for the treatment of HIV. Expert Opin Investig Drugs 2012;21(4):523-30
74. Garrido C, de Mendoza C, Alvarez E, et al. Plasma raltegravir exposure influences the antiviral activity and selection of resistance mutations. AIDS Res Hum Retroviruses 2011;28(2):156-64
75. Kawaguchi I, Ishikawa T, Ishibashi M, et al. Gilead integrase inhibitor: safety and pharmacokinetics of single oral dose of JTK 303/GS-9137, a novel HIV integrase inhibitor, in healthy volunteers [abstract no. 580]. 13th conference on retroviruses and opportunistic infections; 5-8 February 2006; Denver, USA
76. Ramanathan S, Wright M, West S, et al. Pharmacokinetics, metabolism, and excretion of ritonavir-boosted GS-9137 (Elvitegravir) [abstract 30]. 8th International Workshop on Clinical Pharmacology of HIV Therapy; 16-18 April 2007; Budapest, Hungary
77. German P, Warren D, West S, et al. Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing singletablet fixed-dose combination regimen for the treatment of HIV. J Acquir Immune Defic Syndr 2010;55(3):323-9
78. Mathias A, Koziara J, Wei L, et al. Effect of acid reducing agents on the relative bioavailability and pharmacokinetics of cobicistat-boosted elvitegravir [abstract P 13]. 12th International Workshop on Clinical Pharmacology of HIV Therapy; 13-15 April 2011; Miami, USA
79. Acosta EP, Kendall MA, Gerber JG, et al. Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily. Antimicrob Agents Chemother 2007;51(9):3104-10 (Pubitemid 350067515)
80. German P, Wang M, Warren D, Kearney BP. Pharmacokinetic interaction between norgestimate/ethinyl estradiol and EVG/COBI/FTC/TDF single tablet regimen [abstract O-17]. 12th International Workshop on Clinical Pharmacology of HIV Therapy; 13-15 April 2011; Miami, USA
81. Ramanathan S, Shen G, Hinkle J, et al. Pharmacokinetics of coadministered ritonavir-boosted elvitegravir and zidovudine, didanosine, stavudine, or abacavir. J Acquir Immune Defic Syndr 2007;46(2):160-6 (Pubitemid 47485733)
82. Ramanathan S, Shen G, Cheng A, Kearney BP. Pharmacokinetics of emtricitabine, tenofovir, and GS-9137 following coadministration of emtricitabine/tenofovir disoproxil fumarate and ritonavir-boosted GS-9137. J Acquir Immune Defic Syndr 2007;45(3):274-9 (Pubitemid 47012373)
83. Mathias AA, Hinkle J, Shen G, et al. Effect of ritonavir-boosted tipranavir or darunavir on the steady-state pharmacokinetics of elvitegravir. J Acquir Immune Defic Syndr 2008;49(2):156-62
84. Ramanathan S, Kakuda TN, Mack R, et al. Pharmacokinetics of elvitegravir and etravirine following coadministration of ritonavir-boosted elvitegravir and etravirine. Antivir Ther 2008;13(8):1011-17
85. Mathias A, West S, Enejosa J, Kearney B. A pharmacokinetic interaction between lopinavir/r and elvitegravir [abstract A-1418]. 47th Interscience conference on antimicrobial agents and chemotherapy; 17-20 September 2007; Chicago, USA
86. Ramanathan S, Mathias A, Hinkle J, et al. Clinical pharmacokinetics of once-daily elvitegravir boosted by atazanavir versus ritonavir [abstract O18]. 9th International Workshop on Clinical Pharmacology of HIV Therapy; 7-9 April 2008; New Orleans, USA
87. Mathias AA, West S, Hui J, Kearney BP. Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure. Clin Pharmacol Ther 2009; 85(1):64-70
88. Ramanathan S, Mathias A, Shen G, et al. Lack of clinically relevant drug-drug interaction between ritonavir-boosted GS-9137 (elvitegravir) and fosamprenavir/r [abstract WEPEB014]. 4th International conference on HIV pathogenesis, treatment and prevention; 22-25 July 2007; Sydney, Australia
89. Ramanathan S, Abel S, Tweedy S, et al. Pharmacokinetic interaction of ritonavir-boosted elvitegravir and maraviroc. J Acquir Immune Defic Syndr 2009;53(2):209-14
90. Ramanathan S, Wang H, Custodio J, et al. Pharmacokinetics of EVG/COBI/FTC/TDF single tablet regimen following treatment with EFV/FTC/TDF (Atripla) in healthy subjects [abstract O-21]. 13th International Workshop on Clinical Pharmacology of HIV Therapy; 16-18 April 2012; Barcelona, Spain
91. Ruane P, DeJesus E, Berger D, et al. GS-7340 25 mg and 40 mg demonstrate superior efficacy to tenofovir 300 mg in a 10-day monotherapy study of HIV-1+ patients [abstract 103]. 19th Conference on Retroviruses and Opportunistic Infections; 5-8 March 2012; Seattle, USA
92. Ramanathan S, Wei X, Custodio J, et al. Pharmacokinetics of a novel EVG/COBI/FTV/GS-7340 single tablet regimen [abstract O-13]. 13th International Workshop on Clinical Pharmacology of HIV Therapy; 16-18 April 2012; Barcelona, Spain
93. Eron JJ, Young B, Cooper DA, et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet 2010;375(9712):396-407
94. Christ F, Voet A, Marchand A, et al. Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication. Nat Chem Biol 2010;6(6):442-8
95. Ray AS, Cihlar T, Robinson KL, et al. Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother 2006;50(10):3297-304 (Pubitemid 44527501)
96. Fernandez-Fernandez B, Montoya-Ferrer A, Sanz AB, et al. Tenofovir nephrotoxicity: 2011 update. AIDS Res Treat 2011;2011:354908. [Epub 2011 Jun 7]